ANGLE PLC – a small British company changing the world in cancer

Andrew Newland founded ANGLE PLC (AIM:AGL) in 1994. Twenty-eight years on and his company has won FDA clearance for ANGLE's liquid biopsy Parsortix initiative which in the U.S. alone has a $100 billion per annum addressable market.   "We're solving an enormously challenging and important medical question," says Newland who says the ultimate growth of Parsortix is unbounded. For more investment and economics analysis plus inspiration please visit our website masterinvestor.co.uk.